To assess how important ESRP2-regulated mRNAs might be in prostate cancer we monitored associated data for time taken to first biochemical tumour recurrence available in the TCGA PRAD cohort, in which information for 38/44 ESRP-regulated exons was available. This evidence concerns the gene ESRP2 and prostate carcinoma.